Key marijuana drug approval looms as cannabis goes mainstream

LONDON (Reuters) – Evidence that cannabis can ease epilepsy and other conditions is building as a British company counts down to what would be the first U.S. government approval for a prescription drug derived from the marijuana plant.

FILE PHOTO: Charlotte Caldwell, and her son Billy, sit outside the Home Office during a break in a meeting with officials to discuss how Billy can have his severe epilepsy treated with cannabis oil, which is a banned substance in Britain, in London, June 11, 2018. REUTERS/Peter Nicholls/File Photo

GW Pharmaceuticals, which has spent 20 years developing medicines from cannabis, is hoping for a Food and Drug Administration (FDA) green light by June 27, after winning support from an advisory panel in April.

Some parents already use cannabis to help children with severe forms of epilepsy, but such therapy is not monitored or licensed.

Scientists told a briefing in London on Thursday that new research was unlocking the potential of certain cannabis compounds.

    “We’ve learnt a huge amount about cannabis,” said Valerie Curran, head of the clinical psychopharmacology unit at University College London. “It is still early, but it is proving a…

Continue reading at

About Reuters

Since 1850, we have experimented, invented, and created content and news solutions to become the world’s leading international news agency. Always at the forefront of real-time breaking news and high-impact global multimedia content, we are constantly innovating our products and services to meet your business needs. Whether we are serving broadcasters, publishers, brands, agencies, or direct to consumers, Reuters provides award-winning coverage of the day’s most important topics, including: business, finance, politics, sports, entertainment, technology, health, environment, and much more.